RNA Targeting Small Molecule Drug Discovery Market Size Report, 2023-2032
The global RNA targeting small molecule drug discovery market size was exhibited at USD 1.19 billion in 2022 and is projected to hit around USD 7.44 billion by 2032, growing at a CAGR of 20.11% during the forecast period 2023 to 2032.
Key Pointers:
RNA Targeting Small Molecule Drug Discovery Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 1.43 Billion |
| Market Size by 2032 | USD 7.44 Billion |
| Growth Rate From 2023 to 203 | CAGR of 20.11% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Indication, End-user |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Accent Therapeutics; Anima Biotech Inc.; Arrakis Therapeutics; AstraZeneca; Epics Therapeutics; Expansion Therapeutics; Hoffmann-La Roche Ltd; H3 Biomedicine Inc.; PTC Therapeutics; Ribometrix; Servier Laboratories; Skyhawk Therapeutics, Inc |
The increasing demand for RNA targeted small molecule drugs due to their ability to target a broad range of diseases, such as cancer, neurological disorders, and genetic disorders, is expected to drive market growth. Additionally, advancements in RNA targeted drug discovery technologies and increased government funding for RNA research are also contributing to market growth. However, the high cost of drug development and the complexity of RNA based drug discovery are expected to hinder market growth to some extent.
The RNA targeting small molecules drug discovery industry is expected to transform the way the healthcare industry currently treats several diseases. These medications function by specifically targeting RNA molecules, which are appealing drug development targets since they are essential for controlling gene expression. Drugs that target RNA offer the potential to address conditions that have historically been challenging to treat with traditional medications. These include conditions that are caused by mutations in particular genes. Owing to the recently validated advantages of RNA-targeting small molecules, several companies are investing in this novel emerging field. There are several drug candidates in the pipeline, which are anticipated to be launched by 2024 and later.
The RNA targeting small molecules drug discovery industry promises a bright future. However, there are still several obstacles that pose a challenge to its growth. These include the exorbitant cost of medication research. This can reach billions of dollars and is one of the main obstacles. Creating RNA-targeted medications necessitates specialized knowledge and cutting-edge technology, which further raises the price of drug development. Moreover, it may be challenging to find prospective therapeutic candidates due to the intricacy of RNA-based drug discovery, which could add to the expense and length of time needed for drug development. Pharmaceutical corporations are heavily spending on research and development to address these issues, and they are collaborating with academic institutions and contract research groups to hasten the drug discovery and development process.
The COVID-19 pandemic had a mixed impact on the RNA targeting small molecules drug discovery industry. On the one hand, the pandemic has increased the demand for fresh approaches to treating viral illnesses, including those brought on by RNA viruses. By preventing viral RNA from replicating, RNA-targeted medications may be beneficial in treating viral infections. As a result, there is now more interest in developing RNA-targeted medicines to treat COVID-19 and other viral infections.
On the other hand, the pandemic has also hampered efforts to create new drugs because numerous academic institutions and pharmaceutical firms had to transfer funding to COVID-19 research. This has caused funding issues for non-COVID-19 drug discovery initiatives as well as delays in the development of RNA-targeted medications for other disorders. Timelines for drug development have been considerably extended as a result of supply chains and clinical studies being affected by the epidemic. To overcome the challenges posed by the COVID-19 pandemic, pharmaceutical companies have had to adapt and innovate in several ways. One recent example is the partnership between AstraZeneca and the University of Oxford to develop and distribute a COVID-19 vaccine. This partnership involved a collaborative effort to develop a vaccine that was both effective and scalable, which required the use of innovative technologies and processes.
Some of the prominent players in the RNA Targeting Small Molecule Drug Discovery Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global RNA Targeting Small Molecule Drug Discovery market.
By Indication
By End-user
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers